Aridis Pharmaceuticals Inc. (ARDS) stock plunges during current market. Here’s the update
Aridis Pharmaceuticals Inc. (NASDAQ: ARDS) stock declines during the current market by 11.11%. Aridis Pharmaceuticals, Inc. researches and develops anti-infectives that can be used in conjunction with conventional antibiotics to treat infections. Current Development Aridis Pharmaceuticals has signed an exclusive, global licensing deal with AstraZeneca to in-license suvratoxumab, a late-stage monoclonal antibody product. The following […]